

- Ixekizumab is a new anti-interleukin-17A monoclonal antibody that is currently vying for US Food and Drug Administration approval for the treatment of psoriasis.
- In Phase III studies of ixekizumab in the treatment of plaque psoriasis, ixekizumab was shown to have Psoriasis Area and Severity Index 75 values as high as 90% at 12 weeks and continued efficacy through 60 weeks.
- Ixekizumab's safety profile seems favorable, with the most frequently reported adverse events consisting of nasopharyngitis, upper respiratory tract infection, injection-site reaction, and headache.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for publication of this article. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2016. Creative Commons Attribution Noncommercial License (CC BY-NC).